



FEE AUTHORIZATION / AMENDMENT TRANSMITTAL LETTER				PATENT APPLICATION		
Serial No. 09/211.315		Filing Date December 14, 1998		Attorney's Docket No. A-451G		
In the Application of Boyle, William J.		Examiner Carlson, K.		Group Art Unit 1652		
For Osteoprotegerin Binding Proteins						
TO THE ASSISTANT COMMISSIONER FOR PATENTS:						
<input checked="" type="checkbox"/> Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):						
<input checked="" type="checkbox"/> One month of original due date (\$110.00)						
<input type="checkbox"/> Two months of original due date (\$380.00)						
<input type="checkbox"/> Three months of original due date (\$870.00)						
<input type="checkbox"/> Four months of original due date (\$1,360.00)						
<input type="checkbox"/> Five months of original due date (\$1,850.00)						
<input checked="" type="checkbox"/> A response in connection with the matter for which this extension is requested:						
<input checked="" type="checkbox"/> is filed herewith.						
<input type="checkbox"/> has been filed.						
<input type="checkbox"/> The response is the filing of a continuing prosecution application having an express abandonment conditioned on the granting of a filing date to the continuing application.						
<input checked="" type="checkbox"/> The accompanying papers include amended claims for which no additional fee is required.						
<input type="checkbox"/> The accompanying papers include amended claims the fee for which has been calculated as follows:						
CLAIMS AS AMENDED						
(1)	(2) Claims remaining after amendment	(3)	(4) Highest number previously paid for	(5) No. of extra claims present	(6) Rate	(7) Additional Fee
Total Claims	*	Minus	**	=	x \$18	=
Indep. Claims	*	Minus	***	=	x \$78	=
<input type="checkbox"/> First Appearance of a multiple dependent claim					+\$260	=
Total Additional Fee for this Amendment						
*If the entry in column 2 is less than the entry in column 4, write "0" in column 5.						
**If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.						
***If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.						
<input type="checkbox"/> The following other fees are incurred by the accompanying papers.						
<input type="checkbox"/> Other: _____						
Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$110.00. A duplicate copy of this petition is attached.						
<input checked="" type="checkbox"/> If an additional extension of time is required, please consider this a request therefore.						
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.						
<u>Please Send Future Correspondence To:</u>						
US Patent Operations/RBW						
Dept. 430, M/S 27-4-A						
AMGEN INC.						
One Amgen Center Drive						
Thousand Oaks, California 91320-1799						
				Robert B. Winter Attorney/Agent for Applicant(s) Registration No.: 34,458 Phone: (805) 447-2425 Date: March 22, 1999		

#4
B.G.J
4/7/99

RECEIVED

APR 01 1999

MAIL ROOM CUSTOMER
SERVICE CENTER

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

March 22, 1999

Date

Walter Sorenson
Signature

03/30/1999 MARHOL 00000073 010519 09211315
01 FC:115 110.00 CH



Application No.: 09/211315

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE